MS in Black Patients: Not Rare, Often More Aggressive

For most of the 20th century, doctors taught that multiple sclerosis rarely struck Black people. That belief was wrong, and it cost patients years. In a Kaiser Permanente cohort of more than 9 million person-years, Black women had a 59 percent higher risk of developing MS than white women (PMID 23650231). When MS does take hold in Black patients, it tends to be more aggressive: faster progression to disability, more spinal cord and optic nerve damage, and a later diagnosis that lets the disease build a head start.

Multiple sclerosis is an autoimmune disease of the central nervous system. The immune system attacks myelin, the protective coating around nerve fibers in the brain, spinal cord, and optic nerves. Damaged myelin slows or blocks the electrical signals those nerves carry, and over time the nerve fibers themselves can be destroyed (NINDS). Most people start with relapsing-remitting MS: symptoms flare during a relapse, then partly or fully fade, then a new relapse follows weeks, months, or years later. Untreated, many people transition to a progressive phase where disability accumulates steadily (National MS Society).

MS symptoms depend on where the damage lands. The ones that most often signal MS, especially when they come on over hours to days and do not have an obvious cause, include:

• Vision changes: loss of vision in one eye, eye pain on movement, or double vision. This is optic neuritis, and it is a common first sign of MS.
• Numbness or tingling in the face, body, arms, or legs.
• Weakness in one or more limbs.
• Balance and walking problems, clumsiness, or dizziness.
• Severe fatigue that is out of proportion to activity.
• Bladder or bowel changes, including urgency, frequency, or incontinence.
• Heat sensitivity: symptoms that worsen with a hot shower, exercise, or fever.

The pattern matters as much as any single symptom. Neurological symptoms that come, partly resolve, then return in a new spot are the relapsing signature that points to MS.

Older textbooks framed MS as a disease of people of Northern European descent. That framing seeped into clinical instinct: when a young Black patient showed up with numbness, vision loss, or weakness, MS was lower on the list, and other diagnoses got chased first. The result was diagnostic delay. Black patients with MS are diagnosed at an older average age than white patients (mean onset 33.7 versus 31.1 years in one large analysis), and they arrive with more disease already present (PMID 35470139). Delay is not benign in MS. Every relapse can leave permanent nerve damage, and the window where treatment does the most good is early.

The disparity is not only about who gets MS. It is about how hard it hits. In the New York State Multiple Sclerosis Consortium, Black patients had a higher median Multiple Sclerosis Severity Scale score than white patients (6.0 versus 4.8) and were overrepresented in the two most severe disability grades (41.5 percent versus 29.4 percent). The authors concluded that African ancestry is a risk factor for a more rapidly disabling course, and the link held after adjusting for age, sex, disease duration, and treatment (PMID 20644149).

A later cohort found Black patients had higher disability scores at baseline (EDSS 2.9 versus 1.8) and lost brain tissue roughly twice as fast, with gray matter atrophy of 0.9 percent per year versus 0.5 percent and white matter atrophy of 0.7 percent versus 0.3 percent (PMID 35470139). MS in Black patients also concentrates more in the spinal cord and optic nerves, which is why vision loss and walking and bladder problems show up early and hit hard.

Part of the gap is that Black patients have been nearly invisible in the research that shaped treatment. Major disease-modifying therapy trials enrolled Black participants at rates of about 1 to 4 percent (PMID 35470139), so much of what neurologists know about how these drugs work was learned from populations that barely included Black patients. That is a reason to join research when you can, not a reason to wait on treatment.

There is no single MS blood test. A neurologist builds the diagnosis from a few pieces: a detailed history and neurological exam, MRI of the brain and spinal cord to look for the characteristic lesions, and sometimes a lumbar puncture to test spinal fluid for markers of immune activity (NINDS). Just as important, the workup has to rule out conditions that mimic MS and are themselves more common in Black patients. Lupus and sarcoidosis can both inflame the nervous system. So can vitamin B12 or thyroid problems. A thorough neurologist tests for these before settling on MS, and pushes for the imaging rather than writing symptoms off as stress or fatigue.

This is the part of the story that turned. There are now more than a dozen disease-modifying therapies for MS, and several are highly effective at shutting down relapses and slowing nerve damage. The timing matters. In a study of relapsing-remitting MS patients followed for 15 years, staying on immunotherapy cut disability accrual by 19 to 44 percent and reduced the risk of needing a walking aid by 67 percent (Kalincik et al., Neurology, 2021). For Black patients, who tend toward faster progression, getting on an effective therapy early is not a minor optimization. It is the difference between a manageable disease and irreversible disability.

If you have symptoms that fit MS, the goal is a neurologist, ideally one who sees a lot of MS, and an MRI. Do not let the appointment end with a vague reassurance. You can find a Black neurologist or a Black-serving clinician through our directory, which can matter when you need a doctor who takes your symptoms seriously the first time. Bring a written timeline of every symptom, when it started, and whether it came and went. Ask whether you should see an MS specialist or a center that runs clinical trials, since trial enrollment is one way to get cutting-edge therapy and to help close the research gap that has left Black patients underrepresented.